About Anthera Pharmaceuticals
Anthera Pharmaceuticals is a pharmaceutical development company focused on the development and advancement of promising clinical products for the treatment of serious inflammatory diseases. Anthera's lead products have the potential to address a variety of inflammatory diseases including: acute lung injury, acute respiratory distress syndrome, acute chest syndrome, acute coronary syndrome, atherosclerosis, chronic obstructive pulmonary disease and psoriasis.
Missing: Anthera Pharmaceuticals's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Anthera Pharmaceuticals's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Anthera Pharmaceuticals
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Anthera Pharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Anthera Pharmaceuticals Patents
Anthera Pharmaceuticals has filed 2 patents.
Hypolipidemic agents, Heart diseases, Lipid disorders, Cardiology, Vascular diseases
Hypolipidemic agents, Heart diseases, Lipid disorders, Cardiology, Vascular diseases
Latest Anthera Pharmaceuticals News
Aug 2, 2021
Global Atherosclerosis Market Industry Segments, Current and Future Trends, Share Till 2026 Atherosclerosis market players – GlaxoSmithKline plc., Merck & Co., Inc., F. Hoffmann-La Roche Ltd., Isis Pharmaceuticals, Inc., Anthera Pharmaceuticals, Novartis AG, among others represent the global Atherosclerosis market. The market study depicts an extensive analysis of all the players running in the Atherosclerosis market report based on distribution channels, local network, innovative launches, industrial penetration, production methods, and revenue generation. Further, the market strategies and mergers & acquisitions associated with the players are enclosed in the Atherosclerosis market report. Future Market Insights, in its latest business report, elaborates on the current situation of the global Atherosclerosis market in terms of volume, value, production, and consumption. The report scrutinizes the market into various segments, end uses, regions, and players on the basis of demand patterns, and future prospects. Understanding the Impact of Covid-19 on Healthcare Industry With the pandemic plaguing maximum countries across the globe, healthcare industry is witnessing its fair share of ‘ups and downs’. The COVID-19 has placed an enormous strain on the healthcare sector’s workforce, facilities and infrastructure. Despite the endless pressure, healthcare sector is growing at a moderate pace due to the improvement in infrastructure and advancement in technology, healthcare sector is delivering a healthy performance. The FMI’s latest report on the Atherosclerosis market gives a detailed analysis on the impact of COVID-19 with an incisive coverage on the innovative strategies adopted by the market players to survive the challenges due to pandemic. Request For Table Of Content @ https://www.futuremarketinsights.com/toc/rep-gb-2523 Critical Questions Answered in the Report What are ongoing trends that will shape market growth curve for global Atherosclerosis market? What are the drivers and challenges affecting the Atherosclerosis market demand? What are the recent technological advancement in the Atherosclerosis market? What are key trends and opportunities that will prevail the revenue growth of Atherosclerosis market players? How will evolving regulatory policies impact the market growth? What is the impact of Covid-19 on the Atherosclerosis market? Atherosclerosis Market: Segmentation Potential and niche segments, geographical regions exhibiting promising growth A neutral perspective on market performance Must-have information for market players to sustain and enhance their market footprint. Any Queries, Contact Us @ https://www.futuremarketinsights.com/askus/rep-gb-2523 Reasons to Buy the report We provide authentic and detailed an analysis on various market trends to enable businesses to make informed and beneficial decisions to attain competitive edge over key players. Our analysts provide detailed market segmentation along with meaningful insights and extensive reports that other companies fail to include. The report includes accurate analysis of the market and the current developing trends affecting the growth. FMI speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, industry experts. This ensures that the data collected is from highly reliable sources. Why Future Market Insights? Detailed insights of market segments and sub-segments for historical as well as forecast period A competitive analysis of prominent players and emerging players in the Atherosclerosis market Detailed information about the product innovation, mergers and acquisitions lined up in upcoming years Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario Explore Wide-ranging Coverage of FMI’s Healthcare Market Insights Landscape Home Respiratory Therapy Market – Home Respiratory Therapy Market: Global Industry Analysis 2015 – 2019 and Opportunity Assessment 2020 – 2030 Plasma-derived Protein Therapies Market – Plasma-derived Protein Therapies Market: Global Industry Analysis 2015 – 2019 and Opportunity Assessment 2020 – 2030 Olaparib API Market – Olaparib API Market: Global Industry Analysis 2015 – 2019 and Opportunity Assessment 2020 – 2030 About FMI Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers. Contact
Anthera Pharmaceuticals Frequently Asked Questions (FAQ)
When was Anthera Pharmaceuticals founded?
Anthera Pharmaceuticals was founded in 2004.
Where is Anthera Pharmaceuticals's headquarters?
Anthera Pharmaceuticals's headquarters is located at 25801 Industrial Boulevard, Hayward.
What is Anthera Pharmaceuticals's latest funding round?
Anthera Pharmaceuticals's latest funding round is PIPE.
How much did Anthera Pharmaceuticals raise?
Anthera Pharmaceuticals raised a total of $55M.
Who are the investors of Anthera Pharmaceuticals?
Investors of Anthera Pharmaceuticals include OrbiMed Advisors, MPM Capital, VantagePoint Capital Partners, Mitsubishi Corporation Life Sciences Ventures, Sofinnova Ventures and 9 more.
Who are Anthera Pharmaceuticals's competitors?
Competitors of Anthera Pharmaceuticals include Lung Therapeutics and 2 more.
Compare Anthera Pharmaceuticals to Competitors
Revotar Biopharmaceuticals develops anti-inflammatory drugs for inflammatory indications such as psoriasis, acute lung injury (ALI), and chronic obstructive pulmonary disease (COPD). The company was founded in 2000 and is based in Hennigsdorf, Germany.
Pneuma Pharmaceuticals is a private research pharmaceutical company that is developing therapeutic uses for calfactant beyond treatment for respiratory distress syndrome. Pneuma is conducting an international multicenter phase 3 pivotal trial of calfactant for Acute Respiratory Distress Syndrome/Acute Lung Injury in adult patients, which is on track to be completed in 2010. Pneuma Pharmaceuticals has been a member of the incubator since 2008.
Lung Therapeutics pursues treatments for underserved, life-threatening lung conditions. Its therapies for Idiopathic Pulmonary Fibrosis and Loculated Pleural Effusion bring hope to patients whose only treatment options may be invasive surgery or costly and ineffective drugs. The company aims to create better pharmaceutical treatment options for IPF, LPE, and other underserved lung conditions. The company was founded in 2013 and is based in Austin, Texas.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.